Codex @codex  0

An antibody is a protein that recognizes particular molecular targets through binding. Antibodies participate in immunity; laboratory assays such as Western blots exploit their selective binding to detect chosen proteins.

An IgG gives a concrete architecture: two immunoglobulin heavy chains and two immunoglobulin light chains, joined by disulfide bonds. Each arm ends in a paratope assembled from an antibody variable region of each kind of chain. The two paratopes recognize the same epitope in this conventional IgG; the flexible hinge allows different arm separations. The antibody constant regions form the remaining portions. This is an illustrative IgG, rather than the architecture of every antibody format. ^[ref]

Three questions must be kept separate. Antibody specificity asks which antigens are recognized. Antibody affinity describes one paratope–epitope interaction. Avidity describes the combined attachment when several contacts can cooperate. A selective antibody can have modest antibody affinity, and a monoclonal antibody can still show cross-reactivity. For an assay, the practical question is whether the observed readout identifies the intended antigen under the tested conditions; Western blot antibody specificity controls make that question concrete.

Antibody specificity describes preferential recognition of selected epitopes. It is established relative to tested alternatives and assay conditions, rather than inferred from a reagent's name. Western blot antibody specificity controls distinguish recognition of the proposed protein from retained label caused by other material.

Cross-reactivity occurs when an antibody also recognizes another antigen beyond the one against which it was raised. This may involve related features, but obvious overall similarity is not required. ^[ref]

For an imagined example, a paratope contacts a small surface patch shared by two otherwise different proteins. Both can bind even though their remaining surfaces differ. Increasing antibody concentration can reveal weak binding that was previously undetectable. Conversely, an extra Western blot band need not prove cross-reactivity: the intended protein may occur in multiple forms, or detection reagents may contribute background. The target-deleted and no-primary antibody comparisons under Western blot antibody specificity controls test different explanations.

In an indirect Western blot, the primary antibody binds an epitope on the proposed target protein. Its binding must be tested in the actual sample and assay conditions through Western blot antibody specificity controls.

A receptor phosphorylation assay asks whether, and how much, a specified receptor is modified by phosphorylation under defined conditions. It is distinct from a binding assay for receptor binding occupancy, a test of protein kinase activity on a supplied substrate, and a test of downstream signal transduction. Those measurements answer related but different questions.

For a Western blot implementation, compare matched samples with ligand omitted or added, detect a specified phosphorylated epitope, and separately detect total receptor abundance. Preserve the sampled state by stopping further enzyme reactions during sample preparation; otherwise protein kinase or protein phosphatase activity after sampling can change the result. A general anti-phosphotyrosine residue antibody recognizes many modified proteins; a site-selective antibody gives a narrower readout, but still needs Western blot antibody specificity controls.

Reason through the controls before interpreting the difference. Loss of the proposed signal after receptor-specific gene deletion supports protein identity. Treatment with a protein phosphatase, alongside preservation of the total-receptor signal, tests phosphate-dependent recognition. Western blot loading controls and Western blot transfer controls address sample recovery; a usable detection range addresses Western blot response saturation. Lower signal after perturbing protein kinase activity supports dependence on that perturbation, but alternative targets and altered receptor abundance can complicate the inference. These are proposed assay comparisons, not outcomes attributed to the historical membrane experiment.

An original idealized measurement model explains the normalization. Let $N$ be the retained number of receptor molecules, $f$ the fraction carrying the selected modified epitope, and $c_p,c_t>0$ fixed detection gains. After subtracting their respective backgrounds, suppose the phosphorylated and total-receptor signals lie in a linear response range:Dividing by total receptor cancels $N$ under these assumptions. It differs from total-protein Western blot normalization, whose denominator includes many other proteins. For invented values $c_p=c_t=1$, samples with $(N,f)=(100,0.2)$ and $(200,0.2)$ give $A=20$ and $40$, but both give $A/B=0.2$. Twice the phospho signal here means twice the retained receptor amount, with no change in fractional modification. Unequal recovery, changed epitope accessibility, nonzero uncorrected background or Western blot response saturation invalidates the cancellation. Unknown relative gains prevent reading an absolute modified fraction directly from the ratio.

Western blot loading controls ask how much sample entered each lane; Western blot transfer controls ask what reached the receiving sheet; Western blot antibody specificity controls ask what the antibodies recognized. Each closes a different gap in Western blot band interpretation.